Use: Labeled indications
- CABERGOLINE is an ergot derivative indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE CABERGOLINE is an ergot derivative indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults. Limitations of Use Avoid use of CABERGOLINE for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions [see Warnings and Precautions (5.4)].
CABERGOLINE is an ergot derivative indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas in adults. (1) Limitations of Use Avoid use of CABERGOLINE for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions.
(5.4)
Contraindications
4 CONTRAINDICATIONS CABERGOLINE is contraindicated in patients with:
- Uncontrolled hypertension.
- Known hypersensitivity to ergot derivatives.
- History of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis, or history of pericardial fibrosis [see Warnings and Precautions (5.1)].
- History of pleural, pulmonary, or retroperitoneal fibrotic disorders [see Warnings and Precautions (5.2)].
- Uncontrolled hypertension. (4)
- Known hypersensitivity to ergot derivatives. (4)
- History of cardiac valvular disorders, or pericardial fibrosis. (5.1)
- History of pleural, pulmonary, or retroperitoneal fibrotic disorders. (5.2)
Dosing: Adult
- • Before initiating CABERGOLINE evaluate for valvular heart disease, including with an echocardiogram. If valvular disease is detected, do not administer CABERGOLINE. (2.1)
- • Recommended starting dosage of CABERGOLINE is 0.25 mg orally twice weekly. (2.2)
- • Titrate CABERGOLINE to achieve normal serum prolactin levels by increasing CABERGOLINE by 0.25 mg orally twice weekly at intervals of no less than 4 weeks. (2.2)
- • Maximum recommended dosage is 1 mg orally, twice weekly. (2.2)
2.1 Recommended Evaluation
2.1 Recommended Evaluation Before Initiating CABERGOLINE Before initiating CABERGOLINE evaluate for valvular heart disease, including with an echocardiogram. If valvular disease is detected, do not administer CABERGOLINE [see Contraindications (4) and Warnings and Precautions (5.1)].
2.2 Recommended Dosage
2.2 Recommended Dosage The recommended starting dosage of CABERGOLINE is 0.25 mg orally twice weekly. Titrate CABERGOLINE to achieve normal serum prolactin levels by increasing CABERGOLINE by 0.25 mg orally twice weekly at intervals of no less than 4 weeks. The maximum recommended dosage is 1 mg orally, twice weekly [see Warnings and Precautions (5.2)].
Administer CABERGOLINE with or without food [see Clinical Pharmacology (12.3)]. If CABERGOLINE is discontinued, monitor the serum prolactin level periodically to determine whether CABERGOLINE should be reinstituted.
Dosing: Altered kidney function
Patients with Renal Impairment: The pharmacokinetics of cabergoline were not altered in 12 patients with moderate-to-severe renal impairment as assessed by creatinine clearance.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment The use of CABERGOLINE in patients with severe hepatic impairment (HI) (Child-Pugh C) is not recommended. When using CABERGOLINE in patients with moderate HI (Child-Pugh B) increase monitoring of CABERGOLINE-associated adverse reactions. The recommendations for use of CABERGOLINE in patients with mild HI (Child Pugh A) is the same as those with normal hepatic function. Patients with moderate or severe HI had increased cabergoline exposure [see Clinical Pharmacology (12.3)], which may increase the risk of CABERGOLINE-associated adverse reactions.
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of CABERGOLINE in pediatric patients have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of CABERGOLINE did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.
Dosage forms
Philippines
- Tablet: 500 mcg
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Cabergoline as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
CaberlineCabergoline | 500 mcg TabletAlu/Alu blister pack x 10's (Box of 3 blister packs x 10 tablets) | Rx | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DR-XY48152 | Jul 1, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Tablets: 0.5 mg, white, with functional score, oblong scored on one side with the letter P and the letter U on either side of the breakline, engraved with the number 700 on the opposite side. Tablets: 0.5 mg, white, with functional score. (3)
Warnings/Precautions
- • Cardiac Valvulopathy and Pericardial Fibrosis: Before initiating CABERGOLINE, perform a cardiovascular evaluation, including echocardiogram, to evaluate for valvular disease. During CABERGOLINE treatment, monitor for the development of valvulopathy with a cardiac echocardiogram at intervals of 6 to 12 months or as clinically indicated and monitor for chest pain and signs and symptoms of heart failure (if heart failure occurs, exclude valvular fibrosis and pericarditis). Consider additional clinical and diagnostic monitoring at baseline and as necessary during CABERGOLINE treatment. Use CABERGOLINE in patients treated with other drugs associated with valvulopathy only if the potential benefit of CABERGOLINE outweighs the risk. Discontinue CABERGOLINE if the patient has a new diagnosis of valvular regurgitation, valvular restriction, valve leaflet thickening, or pericarditis. (5.1)
- • Pleural, Pulmonary and Retroperitoneal Fibrosis: During CABERGOLINE treatment monitor for signs and symptoms of progressive fibrosis, (e.g., pleuro-pulmonary disease, renal impairment, ureteral/abdominal vascular obstruction). Consider clinical and diagnostic monitoring for pleural, pulmonary, and retroperitoneal fibrosis at baseline and as necessary during CABERGOLINE treatment. If pleural, pericardial, retroperitoneal, or pulmonary fibrosis occur, discontinue CABERGOLINE. (5.2)
- • …
5.1 Cardiac Valvulopathy and Pericardial Fibrosis
5.1 Cardiac Valvulopathy and Pericardial Fibrosis Before initiating CABERGOLINE, perform a cardiovascular evaluation, including with an echocardiogram, to evaluate for valvular disease. CABERGOLINE is contraindicated in the presence of valvular disease or pericardial fibrosis [see Contraindications (4)]. Cases of valvular and pericardial fibrosis have often manifested as heart failure.
Following CABERGOLINE treatment initiation, monitor for the development of valvulopathy with a cardiac echocardiogram at intervals of 6 to 12 months or as clinically indicated with new onset edema, cardiac murmur, dyspnea, or heart failure. During CABERGOLINE treatment, monitor for chest pain and signs and symptoms of heart failure and if heart failure occurs, valvular fibrosis and pericarditis should be excluded.
Consider clinical and diagnostic monitoring such as erythrocyte sedimentation rate, serum creatinine measurements, chest-x- ray, and other investigations and cardiac imaging at baseline and as necessary while patients are treated with during CABERGOLINE treatment. Use CABERGOLINE in patients treated with other drugs associated with valvulopathy only if the potential benefit of CABERGOLINE outweighs the risk.
Discontinue CABERGOLINE if the patient has a new diagnosis of valvular regurgitation, valvular restriction, valve leaflet thickening, or pericarditis. Postmarketing cases of cardiac valvulopathy have been reported in patients who received CABERGOLINE. These cases have generally occurred during administration of high doses of CABERGOLINE (>2 mg/day) for the treatment of Parkinson’s disease (PD) (CABERGOLINE is not approved for the treatment of PD).
Cases of cardiac valvulopathy have also been reported in patients who received lower dosages of CABERGOLINE for the treatment of hyperprolactinemic disorders. In a 12-year, multi-country retrospective cohort study, the use of CABERGOLINE for PD was associated with an increased risk of cardiac valvular regurgitation (CVR).
Compared to non-ergot-derived dopamine agonists and levodopa, CVR with CABERGOLINE use had an incidence rate per 10,000 person years of 68 (95% CI: 37, 115) versus 10 (95% CI: 5, 19) for non-ergot dopamine agonists and 11 (95% CI: 7, 17) for levodopa.
5.2 Pleural, Pulmonary and Retroperitoneal Fibrosis
5.2 Pleural, Pulmonary and Retroperitoneal Fibrosis CABERGOLINE is contraindicated in patients with a history of pleural, pulmonary, or retroperitoneal fibrosis. During CABERGOLINE treatment monitor for signs and symptoms of progressive fibrosis, including:
- Pleuro-pulmonary disease (e.g., dyspnea, shortness of breath, persistent cough, chest pain).
- Renal impairment or ureteral/abdominal vascular obstruction (e.g., pain in the loin/flank, lower limb edema, abdominal masses or tenderness that may indicate retroperitoneal fibrosis). Consider clinical and diagnostic monitoring for pleural, pulmonary, and retroperitoneal fibrosis such as with erythrocyte sedimentation rate, serum creatinine measurements, chest-x-ray, and other investigations at baseline and as necessary during CABERGOLINE treatment. If pleural, pericardial, retroperitoneal, or pulmonary fibrosis occur, discontinue CABERGOLINE. Postmarketing cases of pleural, pulmonary, and retroperitoneal fibrosis have been reported following CABERGOLINE administration. Some reports were in patients previously treated with other ergotinic dopamine agonists. CABERGOLINE-treated patients who developed a pleural effusion or pulmonary fibrosis and subsequently discontinued CABERGOLINE had improvement of their pulmonary symptoms.
5.3 Orthostatic Hypotension
5.3 Orthostatic Hypotension Check blood pressure at baseline and during treatment with CABERGOLINE and monitor for orthostatic hypotension. Warn patients about the risk of orthostatic hypotension and precautions to take when rising from a supine or sitting position. Instruct patients to report dizziness or lightheadedness with changes in position to their healthcare provider.
CABERGOLINE can cause orthostatic hypotension [see Adverse Reactions (6.1)]. In a 4-week, placebo-controlled trial in patients with hyperprolactinemic disorders, the percentage of CABERGOLINE-treated patients and placebo-treated patients who developed orthostatic hypotension was 4% and 0%, respectively [see Adverse Reactions (6.1)].
The risk of orthostatic hypotension is greater in CABERGOLINE-treated patients when taking concomitant drugs that lower blood pressure.
5.4 Risks with Use
5.4 Risks with Use of CABERGOLINE for Postpartum Lactation Inhibition or Suppression Avoid use of CABERGOLINE for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions. Use of bromocriptine, another dopamine agonist for this unapproved use has been associated with cases of hypertension, stroke, myocardial infarction seizures, and death.
5.5 Impulse Control Disorders and Compulsive Behaviors
5.5 Impulse Control Disorders and Compulsive Behaviors Because patients may not recognize impulse control and compulsive behaviors as abnormal, it is important for health care providers to specifically ask patients about the development of new or increased gambling urges, sexual urges, uncontrolled spending, or other urges while being treated with CABERGOLINE. Consider dosage reduction or stopping CABERGOLINE if a patient develops such urges while taking CABERGOLINE.
Patients can experience intense urges to gamble or to spend money, increased sexual urges, binge eating, and/or other intense urges, and the inability to control these urges while taking one or more drugs that increase central dopaminergic tone, including CABERGOLINE. In some cases, these urges were reported to have stopped when the dosage was reduced, or the drug was stopped.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS CABERGOLINE, a dopamine receptor agonist, is not recommended for concomitant use with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide. CABERGOLINE, a dopamine receptor agonist, is not recommended for concomitant use with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide. (7)
Adverse reactions
The following clinically significant adverse reactions are described elsewhere in the labeling:
- Cardiac Valvulopathy and Pericardial Fibrosis [see Warnings and Precautions (5.1)].
- Pleural, Retroperitoneal, and Pulmonary Fibrosis [see Warnings and Precautions (5.2)].
- Orthostatic Hypotension [see Warnings and Precautions (5.3)].
- Impulse Control Disorders and Compulsive Behaviors [see Warnings and Precautions (5.5)]. The most common adverse reactions (incidence >10%) are nausea, headache, and dizziness. (6) To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1‑877‑4‑INFO‑RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of CABERGOLINE has been evaluated in more than 900 patients with hyperprolactinemic disorders.
In a 4-week, double-blind, placebo-controlled trial (CABERGOLINE vs. placebo) [see Clinical Studies (14)], the incidence of the most common adverse reactions during the placebo-controlled trial in patients with hyperprolactinemic disorders is presented in Table 1. Table 1. Adverse Reactions (n (%)) Adverse reactions that occurred ≥1% in the CABERGOLINE group and frequency more than that reported in the placebo group.
During the 4-Week, Double-Blind, Placebo-Controlled Trial in Hyperprolactinemic Females CABERGOLINE (n=168) Placebo (n=20) Nausea 45 (27%) 4 (20%) Headache 43 (26%) 5 (25%) Dizziness 25 (15%) 1 (5%) Constipation 16 (10%) 0% Fatigue 12 (7%) 0% Postural hypotension 6 (4%) 0% Dyspepsia 4 (2%) 0% Vomiting 4 (2%) 0% Nervousness 4 (2%) 0% Vertigo 2 (1%) 0% Paresthesia 2 (1%) 0% Breast pain 2 (1%) 0% Dysmenorrhea 2 (1%) 0% Abnormal vision 2 (1%) 0% In the 8-week, double-blind period of the comparative trial with bromocriptine, 2% (4/221) of CABERGOLINE-treated patients (0.5 mg twice weekly) discontinued treatment because of an adverse event and 6% (14/231) of bromocriptine-treated patients (at a dose of 2.5 mg twice daily) discontinued treatment because of an adverse event. The most common reasons for CABERGOLINE discontinuation were headache, nausea, and vomiting (3, 2, and 2 patients, respectively).
The incidence of the most common adverse events during the double-blind period of the comparative trial with bromocriptine is presented in Table 2. Table 2. Adverse Events Adverse events reported ≥1% in the CABERGOLINE group. Abbreviation: n=number of patients. During the 8-Week, Double-Blind Period of the Comparative Trial in Hyperprolactinemic Females CABERGOLINE (n=221) Bromocriptine (n=231) Nausea 63 (29%) 100 (43%) Headache 58 (26%) 62 (27%) Dizziness 38 (17%) 42 (18%) Constipation 15 (7%) 21 (9%) Asthenia 13 (6%) 15 (6%) Abdominal pain 12 (5%) 19 (8%) Dyspepsia 11 (5%) 16 (7%) Fatigue 10 (5%) 18 (8%) Vertigo 9 (4%) 10 (4%) Vomiting 9 (4%) 16 (7%) Depression 7 (3%) 5 (2%) Hot flashes 6 (3%) 3 (1%) Breast pain 5 (2%) 8 (3%) Dry mouth 5 (2%) 2 (1%) Paresthesia 5 (2%) 6 (3%) Somnolence 5 (2%) 5 (2%) Diarrhea 4 (2%) 7 (3%) Flatulence 4 (2%) 3 (1%) Pain 4 (2%) 6 (3%) Acne 3 (1%) 0% Anorexia 3 (1%) 3 (1%) Anxiety 3 (1%) 3 (1%) Hypotension 3 (1%) 4 (2%) Insomnia 3 (1%) 2 (1%) Syncope 3 (1%) 3 (1%) Abnormal vision 2 (1%) 2 (1%) Arthralgia 2 (1%) 0% Dependent edema 2 (1%) 1 (<1%) Dysmenorrhea 2 (1%) 1 (<1%) Impaired concentration 2 (1%) 1 (<1%) Influenza-like symptoms 2 (1%) 0% Malaise 2 (1%) 0% Nervousness 2 (1%) 5 (2%) Palpitation 2 (1%) 5 (2%) Periorbital edema 2 (1%) 2 (1%) Peripheral edema 2 (1%) 1 (<1%) Pruritus 2 (1%) 1 (<1%) Rhinitis 2 (1%) 9 (4%) Throat irritation 2 (1%) 0% Toothache 2 (1%) 0% Events that were reported at an incidence of <1% in the clinical studies follow:
- Body As a Whole: facial edema, influenza-like symptoms, malaise
- Cardiovascular System: hypotension, syncope, palpitations
- Digestive System: dry mouth, flatulence, diarrhea, anorexia
- Metabolic and Nutritional System: weight loss, weight gain
- Nervous System: somnolence, nervousness, paresthesia, insomnia, anxiety
- Respiratory System: nasal stuffiness, epistaxis
- Skin and Appendages: acne, pruritus
- Special Senses: abnormal vision
- Urogenital System: dysmenorrhea, increased libido
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of CABERGOLINE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Psychiatric: impulse control disorders and compulsive behaviors including, hypersexuality, increased libido, pathological gambling; psychotic disorder, aggression
- Skin and subcutaneous: alopecia
Adverse reaction frequency tables (US label) US FDA label
| CABERGOLINE(n=168) | Placebo(n=20) | |
| Nausea | 45 (27%) | 4 (20%) |
| Headache | 43 (26%) | 5 (25%) |
| Dizziness | 25 (15%) | 1 (5%) |
| Constipation | 16 (10%) | 0% |
| Fatigue | 12 (7%) | 0% |
| Postural hypotension | 6 (4%) | 0% |
| Dyspepsia | 4 (2%) | 0% |
| Vomiting | 4 (2%) | 0% |
| Nervousness | 4 (2%) | 0% |
| Vertigo | 2 (1%) | 0% |
| Paresthesia | 2 (1%) | 0% |
| Breast pain | 2 (1%) | 0% |
| Dysmenorrhea | 2 (1%) | 0% |
| Abnormal vision | 2 (1%) | 0% |
| CABERGOLINE(n=221) | Bromocriptine(n=231) | |
| Nausea | 63 (29%) | 100 (43%) |
| Headache | 58 (26%) | 62 (27%) |
| Dizziness | 38 (17%) | 42 (18%) |
| Constipation | 15 (7%) | 21 (9%) |
| Asthenia | 13 (6%) | 15 (6%) |
| Abdominal pain | 12 (5%) | 19 (8%) |
| Dyspepsia | 11 (5%) | 16 (7%) |
| Fatigue | 10 (5%) | 18 (8%) |
| Vertigo | 9 (4%) | 10 (4%) |
| Vomiting | 9 (4%) | 16 (7%) |
| Depression | 7 (3%) | 5 (2%) |
| Hot flashes | 6 (3%) | 3 (1%) |
| Breast pain | 5 (2%) | 8 (3%) |
| Dry mouth | 5 (2%) | 2 (1%) |
| Paresthesia | 5 (2%) | 6 (3%) |
| Somnolence | 5 (2%) | 5 (2%) |
| Diarrhea | 4 (2%) | 7 (3%) |
| Flatulence | 4 (2%) | 3 (1%) |
| Pain | 4 (2%) | 6 (3%) |
| Acne | 3 (1%) | 0% |
| Anorexia | 3 (1%) | 3 (1%) |
| Anxiety | 3 (1%) | 3 (1%) |
| Hypotension | 3 (1%) | 4 (2%) |
| Insomnia | 3 (1%) | 2 (1%) |
| Syncope | 3 (1%) | 3 (1%) |
| Abnormal vision | 2 (1%) | 2 (1%) |
| Arthralgia | 2 (1%) | 0% |
| Dependent edema | 2 (1%) | 1 (<1%) |
| Dysmenorrhea | 2 (1%) | 1 (<1%) |
| Impaired concentration | 2 (1%) | 1 (<1%) |
| Influenza-like symptoms | 2 (1%) | 0% |
| Malaise | 2 (1%) | 0% |
| Nervousness | 2 (1%) | 5 (2%) |
| Palpitation | 2 (1%) | 5 (2%) |
| Periorbital edema | 2 (1%) | 2 (1%) |
| Peripheral edema | 2 (1%) | 1 (<1%) |
| Pruritus | 2 (1%) | 1 (<1%) |
| Rhinitis | 2 (1%) | 9 (4%) |
| Throat irritation | 2 (1%) | 0% |
| Toothache | 2 (1%) | 0% |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary If conception occurs during CABERGOLINE therapy, discontinue CABERGOLINE if the risks to the mother or fetus outweigh the benefits to the mother. There are risks to the mother associated with the use of CABERGOLINE (see Clinical Considerations). The estimated background risk of major birth defects and miscarriage in patients with hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas is unknown.
All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Maternal Adverse Reactions: In general, avoid use of dopamine agonists, including CABERGOLINE, during pregnancy and the postpartum period.
The risks of CABERGOLINE use increase in pregnant females with pregnancy-induced hypertension, preeclampsia, and eclampsia. Data Human Data: Published case reports have not reported a clear association with CABERGOLINE and major birth defects, miscarriage, or adverse fetal outcomes when CABERGOLINE was used during early pregnancy.
However, these case reports cannot definitely establish the absence of CABERGOLINE-associated risk. Animal Data: Embryo-fetal development studies have been performed with cabergoline administered by oral gavage in mice, rats, and rabbits:
- There were no teratogenic effects in the presence of maternal toxicity in mice given cabergoline at doses up to 8 mg/kg/day (approximately 55 times the maximum recommended human dose based on body surface area) during the period of organogenesis.
- A dose of 0.012 mg/kg/day (approximately 0.14 times the maximum recommended human dose) administered during the period of organogenesis in rats caused an increase in post-implantation loss. This finding is likely due to the role of prolactin in implantation in rats and is not thought to be relevant to humans.
- At doses of 0.5 mg/kg/day (approximately 19 times the maximum recommended human dose) administered during the period of organogenesis in rabbits, cabergoline caused maternal toxicity characterized by a loss of body weight and decreased food consumption. Doses of 4 mg/kg/day (approximately 150 times the maximum recommended human dose) administered during the period of organogenesis in the rabbit caused an increased occurrence of various malformations. However, in another study in rabbits, no treatment-related malformations or embryofetal toxicity were observed at doses up to 8 mg/kg/day (approximately 300 times the maximum recommended human dose).
Mechanism of action
12.1 Mechanism of Action Cabergoline is an ergot derivative and dopamine receptor agonist with a high affinity for D2 receptors. Results of in vitro studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. Cabergoline decreased serum prolactin levels in reserpinized rats. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D1, α1- and α2-adrenergic, and 5-HT1- and 5-HT2-serotonin receptors.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of CABERGOLINE have not been fully characterized.
Pharmacokinetics
Elimination The elimination half-life of cabergoline estimated from urinary data of 12 healthy subjects ranged between 63 to 69 hours.
Excretion: After oral dosing of radioactive cabergoline to 5 healthy volunteers, approximately 22% and 60% of the dose was excreted within 20 days in the urine and feces, respectively.
Less than 4% of the dose was excreted unchanged in the urine.
Nonrenal and renal clearances for cabergoline are about 3.2 L/min and 0.08 L/min, respectively.
Urinary excretion in hyperprolactinemic patients was similar.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption The time to reach maximum cabergoline plasma concentration was 2 to 3 hours after single oral doses of 0.5 mg to 1.5 mg (1.5 times the maximum recommended dose) of CABERGOLINE in healthy subjects. Following dosing of CABERGOLINE between 0.5 mg to 7 mg (7 times the maximum recommended dose), cabergoline plasma levels appeared to be dose-proportional.
The absolute bioavailability of cabergoline is unknown. A significant fraction of the administered dose undergoes a first-pass effect. Effect of Food: High-fat food did not alter the pharmacokinetics of cabergoline [see Dosage and Administration (2.2)]. Distribution Protein binding of cabergoline was 40% to 42%. Elimination The elimination half-life of cabergoline estimated from urinary data of 12 healthy subjects ranged between 63 to 69 hours.
Metabolism: Cabergoline is extensively metabolized, predominately via hydrolysis of the acylurea bond or the urea moiety. Hydrolysis of the acylurea or urea moiety abolishes the prolactin-lowering effect of cabergoline, and major metabolites identified thus far do not contribute to the therapeutic effect. Excretion: After oral dosing of radioactive cabergoline to 5 healthy volunteers, approximately 22% and 60% of the dose was excreted within 20 days in the urine and feces, respectively.
Less than 4% of the dose was excreted unchanged in the urine. Nonrenal and renal clearances for cabergoline are about 3.2 L/min and 0.08 L/min, respectively. Urinary excretion in hyperprolactinemic patients was similar. Specific Populations Patients with Hepatic Impairment: In a pharmacokinetic hepatic impairment (HI) study [see Use in Specific Populations (8.6)]:
- In 4 CABERGOLINE-treated patients with mild HI (Child-Pugh A), no effect on mean area under the cabergoline plasma concentration-time curve (AUC) was observed.
- In 4 CABERGOLINE-treated patients with moderate HI (Child-Pugh B) there was a 1.5-fold increase in mean cabergoline AUC.
- In 4 CABERGOLINE-treated patients with severe HI (Child-Pugh C) there was a 5.6-fold increase in the mean cabergoline AUC. Male and Female Patients: Males aged 20 to 34 years were shown to have had higher C max than females aged 20 to 27 years) while males aged 66 to 75 years had lower C max compared to females aged 66 to 74 years. The clinical significance of the findings is unknown. Patients with Renal Impairment: The pharmacokinetics of cabergoline were not altered in 12 patients with moderate-to-severe renal impairment as assessed by creatinine clearance.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Cabergoline · Mylan Pharmaceuticals Inc. [US FDA-approved label, version 12, June 30, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e497366b-a124-4d7f-bd45-a883c392d4bb
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
